
    
      Eligible patients are randomly allocated to receive either bevacizumab with raltitrexed and
      oxaliplatin combination or bevacizumab with FOLFOX 6 combination. Random allocation schedule
      is performed using a minimization technique for the following stratification factors:

        -  Center

        -  Number of metastatic sites: 1 versus > 1

        -  Bevacizumab-based first-line therapy: Yes versus No
    
  